Literature DB >> 10497008

Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy.

S J Chavan1, S L Tamma, M Kaplan, M Gersten, S G Pahwa.   

Abstract

Patients with HIV infection manifest increased T lymphocyte apoptosis. This study investigated the influence of antiretroviral therapy (ART) upon lymphocyte apoptosis in 23 HIV-infected adults naive to protease inhibitors. Patients were enrolled in a treatment trial consisting of Nelfinavir (NFV), d4T, or NFV + d4T for 24 weeks, followed by triple therapy (NFV + reverse transcriptase inhibitors) for an additional 24 weeks. Spontaneous T cell apoptosis in cultured PBMC decreased by 23.67 +/- 18.2% (P < 0.006) at 48 weeks and plasma HIV RNA decreased by 1.79 +/- 0.59 log(10) RNA copies/ml (P < 0.001). The absolute decrease and slope of T cell apoptosis correlated with plasma virus load and with activated CD8 T cells and was inversely correlated with CD4 T cells. We conclude that reduction in chronic antigenic stimulation and the absence of cellular signals elicited by viral products contribute to the rescue of T lymphocytes from apoptosis, which facilitates immunologic recovery in ART-treated patients. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497008     DOI: 10.1006/clim.1999.4770

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  12 in total

Review 1.  Nelfinavir: an update on its use in HIV infection.

Authors:  A Bardsley-Elliot; G L Plosker
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery.

Authors:  David L Pitrak; Richard M Novak; Randee Estes; Jean Tschampa; Christina D Abaya; Jeffrey Martinson; Kirsten Bradley; Allan R Tenorio; Alan L Landay
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11-11       Impact factor: 2.205

3.  Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death.

Authors:  Jérôme Estaquier; Jean-Daniel Lelièvre; Frédéric Petit; Thomas Brunner; Laure Moutouh-De Parseval; Douglas D Richman; Jean Claude Ameisen; Jacques Corbeil
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 4.  Nelfinavir: a review of its use in the management of HIV infection.

Authors:  Caroline M Perry; James E Frampton; Paul L McCormack; M Asif A Siddiqui; Risto S Cvetković
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals.

Authors:  M Paiardini; D Galati; B Cervasi; G Cannavo; L Galluzzi; M Montroni; D Guetard; M Magnani; G Piedimonte; G Silvestri
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Response to superantigen stimulation in peripheral blood mononuclear cells from children perinatally infected with human immunodeficiency virus and receiving highly active antiretroviral therapy.

Authors:  Thomas W McCloskey; Viraga Haridas; Lucy Pontrelli; Savita Pahwa
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

7.  T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384.

Authors:  Todd Hulgan; Gregory K Robbins; Spyros A Kalams; David C Samuels; Benjamin Grady; Robert Shafer; Deborah G Murdock; Doug Selph; David W Haas; Richard B Pollard
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

Review 8.  Immune reconstitution disease associated with parasitic infections following antiretroviral treatment.

Authors:  S D Lawn; R J Wilkinson
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

9.  Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells.

Authors:  Nathan W Cummins; Amy M Sainski; Sekar Natesampillai; Gary D Bren; Andrew D Badley
Journal:  Mol Cell Ther       Date:  2014-01-03

Review 10.  Role of the Fas/FasL pathway in HIV or SIV disease.

Authors:  Bhawna Poonia; C David Pauza; Maria S Salvato
Journal:  Retrovirology       Date:  2009-10-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.